Breaking News, Financial News

Financial Report: Alexion 3Q

Revenues up 44% in the quarter

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Alexion 3Q Revenues: $294.1 million (+44%) 3Q Earnings: $92.2 million (+41%) YTD Revenues: $813.6 million (+46%) YTD Earnings: $173.9 million (+37%) Comments: Soliris sales were $294.1 million in the quarter, up 44%. R&D expenses were $54.3 million, compared to $36.6 million in 3Q11. Results were positively impacted by the terms of a patent settlement and license agreement, for which the company recognized a gain of $53.4 million in cost of sales, net of the effect of an upfront payment...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters